| Industry | 制造业 | ||||||||||||||||||||||||
| Company Introduction | 公司是一家专注于电生理和血管介入医疗器械的研发、生产和销售的高新技术企业，已形成了以完整冠脉通路和电生理医疗器械为主导，外周血管和神经介入医疗器械为重点发展方向的业务布局。公司是国产电生理和血管介入医疗器械品种品类齐全、规模领先、具有较强市场竞争力的企业之一，也是能够与国外产品形成强有力竞争的为数不多的企业之一。 根据弗若斯特沙利文的相关研究报告，按照产品销售金额排名，2019年公司在电生理医疗器械国产品牌中市场份额排名第一，在冠脉通路医疗器械国产品牌中市场份额排名第三。 在电生理医疗器械领域，公司是中国第一家获得电生理电极导管、可控射频消融电极导管、漂浮临时起搏电极导管市场准入并进入临床应用的国产厂家，填补了电生理领域国产品牌的空白，同时于2011年成为中国首家获得电生理电极导管和可控射频消融电极导管两类产品欧盟CE认证的国产厂家。在血管介入器械领域，公司是国内首家获得微导管（冠脉应用）、外周可调阀导管鞘（导管鞘组）、导引延伸导管和薄壁鞘（血管鞘组）市场准入的国产厂家，公司的导引延伸导管和薄壁鞘（血管鞘组）是国内唯一获批上市的国产产品。 公司在电生理、血管介入医疗器械的研发和生产领域拥有丰富的技术积累和人才储备，攻关并掌握了“钢丝网加强挤出”、“亲水涂层”、“异种合金对接”等多种国外垄断的通路类产品必备产业化技术，同时具备独立生产导管、球囊、导丝等多种血管介入产品的高端生产制造能力。公司坚持自主研发创新，同时积极发掘临床需求，利用公司在行业内领先的生产制造能力实现可充分满足临床需求产品的产业化。截至2020年8月31日，公司共拥有国内外专利证书65项，其中国内发明专利40项，国外发明专利2项。 经过多年的发展，公司已在境内外建立了完善的销售网络，覆盖全国31个省、自治区和直辖市的700余家三甲医院及680余家县市级二甲医院，并出口至欧洲、美洲、东南亚的80多个国家和地区。 | ||||||||||||||||||||||||
| Main Business | 电生理和血管介入医疗器械的研发、生产和销售。 | ||||||||||||||||||||||||
| Legal Representative | 葛昊 | ||||||||||||||||||||||||
| Top Executives |
|
||||||||||||||||||||||||
| Top 5 Shareholder |
|
||||||||||||||||||||||||
| Company Secretary | 戴振华 | ||||||||||||||||||||||||
| Solicitors | 北京市嘉源律师事务所 | ||||||||||||||||||||||||
| Auditors | 立信会计师事务所（特殊普通合伙） | ||||||||||||||||||||||||
| Tel No | 0755-86951506 | ||||||||||||||||||||||||
| Fax No | 0755-83480508;0755-26030108 | ||||||||||||||||||||||||
| Website | www.aptmed.com | ||||||||||||||||||||||||
| ir@aptmed.com | |||||||||||||||||||||||||
| Company Address |
|
||||||||||||||||||||||||
| Listing Date | 07/01/2021 | ||||||||||||||||||||||||
| Shares Capital |
|
||||||||||||||||||||||||
| EPS(RMB)* | ¥ 8.040 | ||||||||||||||||||||||||
| DPS(RMB)* | ¥ 2.000 | ||||||||||||||||||||||||
| NBV Per Share(RMB)* | ¥ 28.524 | ||||||||||||||||||||||||
| Market Capitalization(RMB) | 36.623B |
 |
Only Chinese content is avaliable |
|
N
/
N
: Eligible Stock for SH-HK Northbound trade (For all investors/ For institutional professional investors only)
N
: Eligible Stock for SH-HK Ex-Northbound trade (sell only)
|
|
|
N
/
N
: Eligible Stock for SZ-HK Northbound trade (For all investors/ For institutional professional investors only)
N
: Eligible Stock for SZ-HK Ex-Northbound trade (sell only)
|
|
| * | Unadjusted Data |
| Information provided by: etnet | ||
| Terms and Conditions | ||
| Risk Disclosure: |
| The prices of securities may fluctuate, sometimes dramatically. The price of a security may move up or down, and may become valueless. It is as likely that losses will be incurred rather than profit made as a result of buying and selling securities. The information is for reference only, it does not constitute any offer, solicitation, recommendation, comment or any guarantee to the purchase or sale of any investment product or service. Customers should not make any investment decisions based on this information alone. |
| Disclaimer: |
| This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources, Nanyang Commercial Bank Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information. |